IMHO, the SEC issue needs to occupy the time of DECNs lawyers and should have little to no impact on the testing validation. Two distinct issues/initiatives and should be handled by two distinct functions. Some oversight by Berman on both, but the guy is the CEO and has resources to apply to this stuff.

IMHO, and this is as straight as I can say, this companies survival as a business and credibility as a company and leadership team hinges on FDA approval of GenViro.

FDA approval alleviates SEC issues (which are a bunch of BS IMI), paves the way to disrupt a huge addressable market, opens the door for the diabetic business, ensures uplisting off greys, and offers the company numerous monetizing opportunities.

No approval and the court of public opinion will likely set this company back years in many ways. Essentially, it becomes uninvestable and illiquid.

Also, the canal crap is just that crap. These clowns exist for all stocks and esp. micro bios and even more if disruptive capability exists. I wouldn’t waste any time as a company chasing these guys. Some are paid, some are just assholes and some are just trying to make a greedy ass buck. IMO, don’t entertain them, respond to them or chase them.

So, keep the laser like focus on testing, work with the FDA and any others helping and get it done. The rest is noise and has no bearing on FDA testing validation.

That’s my straight shooting take.